Evidence map›Paper›PMID 32602076›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.

G Francolini, B Detti, M Bottero, T Zilli, A Lancia, A Bruni, S Borghesi, M Mariotti, P Castellucci, S Fanti and 7 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Scientific reports · 2022
    Article
  7. Article
  8. Review
  9. Evaluation ofTranslational oncology · 2022
    Article
  10. Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point-a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  11. Diagnostics (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

G FrancoliniRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy. francolinigiulio@gmail.com.ORCID http://orcid.org/0000-0002-1784-7203
B DettiRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
M BotteroDepartment of Radiation Oncology, Policlinico Tor Vergata, University of Rome, Rome, Italy.
T ZilliRadiation Oncology Division, Geneva University Hospital, Geneva, Switzerland.
A LanciaRadiation Oncology Unit, Department of Medical Sciences and Infectious Disease, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.
A BruniRadiotherapy Unit, University Hospital of Modena, Modena, Italy.
S BorghesiUOC Radiation Oncology Arezzo-Valdarno, Azienda USL Toscana Sud Est, Arezzo, Italy.
M MariottiRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
P CastellucciDepartment of Nuclear Medicine, Policlinico S. Orsola-Malpighi, Bologna, Italy.
S FantiDepartment of Nuclear Medicine, Policlinico S. Orsola-Malpighi, Bologna, Italy.
A R FilippiRadiation Oncology Unit, Department of Medical Sciences and Infectious Disease, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.
M A TeriacaRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
V MaragnaRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
C AristeiRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
E MazzeoRadiotherapy Unit, University Hospital of Modena, Modena, Italy.
L LiviRadiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Largo G. A. Brambilla 3, 50134, Florence, Italy.
G IngrossoRadiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITUniversity of Pavia · ITUniversity of Perugia · ITAzienda Usl 8 Arezzo · ITPoliclinico Tor Vergata · ITUniversity Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims

results92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (p = 0.004) and TTR < 29.5 months (p = 0.003).

conclusionsPSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.

Indexed as

Gallium IsotopesGallium RadioisotopesPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAgedAndrogen AntagonistsAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProstatectomyProstate-Specific AntigenAndrogen AntagonistsAntigens, SurfaceFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIProstate-Specific AntigenRadiopharmaceuticalsBiochemical recurrenceProstate cancerPSMA PETRadiotherapy

Identifiers

PMID32602076
OpenAlexW3040541183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.